Company intelligence / Profile preview

BIGESPAS Ltd

Ownership: Private
Development stage: Phase 2

Overview

BIGESPAS Ltd is developing an anti-Alzheimer's drug based on the DMB-I polymorph of Latrepirdine (Dimebon®). The company holds an international patent for this know-how and began Phase II trials in 2023 following successful animal studies. In 2022, they acquired control over the Dimebon® medicine to facilitate product development[1].

Therapeutic areas: Neurology
Modalities: Small molecules (specifically Latrepirdine/Dimebon® DMB-I)
Industry: Biotech

Drug pipeline

1 asset

latrepirdine

Phase 2

Indications: Dementia Associated With Alzheimer's Disease

Beyond the preview

Go deeper on BIGESPAS Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIGESPAS Ltd.

Explore the full profile